Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 99,63 € (-19,82%). La mediana è 105,49 € (-15,11%).
| Acquista |
8 |
| Mantieni |
16 |
| Vendi |
5 |
Notizie Vai al feed delle notizie
Bamco bought Moderna before shares nearly tripled
Bamco, the advisory arm of Baron Capital Group, opened a new roughly 2 million‑share position in Moderna during Q2 2026. The timing proved favorable as Moderna stock almost tripled in August following a positive Phase 3 trial report. » Altro su finance.yahoo.com
Moderna closes $3 billion convertible notes and shares jump
Moderna privately placed interest-free convertible notes totaling $3 billion (including an exercised option of $400 million) maturing in March 2032 with an initial conversion price of about $211 per share. Net proceeds of roughly $2.96 billion will, according to the company, go to the oncology division and debt reduction; about $329 million were used for cap hedges against dilution. If fully converted, up to approximately 14.2 million new shares could be issued; investors will watch the conversion price as a reference for potential future dilution. » Altro su finanzen.net
Moderna closes $3 billion convertible bond and expands oncology unit
Moderna placed a zero‑coupon convertible bond totaling $3 billion (including a $400 million option) maturing in March 2032; the initial conversion price is about $211 per share. Net proceeds will be used to strengthen the oncology unit and to pay down debt; roughly $329 million went into cap hedges against dilution (cap price about $393). The stock jumped nearly 10% on the announcement before an after‑hours pullback, after positive Phase‑III data for the cancer vaccine Intismeran had already driven strong gains. If fully converted, up to about 14.2 million new shares could be issued, representing potential dilution for shareholders. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 127,05 Mln | 5,46% |
| Utile lordo | 45,56 Mln | 133,49% |
| Utile netto | -685,2 Mln | 2,11% |
| EBITDA | -616,85 Mln | 4,33% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 49,73 Mld € |
Numero di azioni | 396,79 Mln |
Massimo/minimo a 52 settimane | 152,12 € - 19,19 € |
| Dividendi | No |
Beta | 0,90 |
Rapporto P/E | -18,24 |
Rapporto PEG | 2,16 |
Rapporto P/B | 8,53 |
Rapporto P/S | 25,92 |
Profilo aziendale
Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.
| Nome | Moderna Inc. |
| CEO | Stéphane Bancel |
| Sede centrale | Cambridge,
ma Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 07/12/2018 |
| Dipendenti | 4700 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | MRNA |
XETRA | 0QF.F |
Frankfurt | 0QF.F |
Düsseldorf | 0QF.DU |
Hamburg | 0QF.HM |
Milan | 1MRNA.MI |
London | 0A45.L |
SIX | 0QF.SW |
München | 0QF.MU |
Wien | MRNA.VI |
Scopri gli asset
Gli azionisti di Moderna Inc. investono anche nei seguenti asset